Physician profile
Benjamin D Margolis
NPI 1174600514
$3,859.28
in general payments reported to CMS, 2019-2025
18 companies · $1,204 in 2025
The $1,204 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264 · 2020: $25.71 · 2021: $215 · 2022: $384 · 2023: $537 · 2024: $1,229 · 2025: $1,204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,959 · Education: $10.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,959.39 |
| Education | $10.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,327.69 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $472.94 | 2023-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| United Therapeutics Corporation | $431.22 | 2024-2025 | |
| Inspire Medical Systems, INC. | $297.35 | 2022-2023 | Inspire |
| Pulmonx Corporation | $283.16 | 2022-2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Harmony Biosciences LLC | $163.67 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $124.26 | 2024 | Dupixent |
| Genzyme Corporation | $120.60 | 2025 | |
| Glaxosmithkline, LLC. | $120.60 | 2025 | Nucala |
| Genentech USA, INC. | $112.78 | 2019 | |
| Philips North America LLC | $112.47 | 2023-2025 | (Ak6) Vest Therapy, Vest Therapy Und, Patient Interface Software |
| Salvin Dental Specialties, INC. | $92.09 | 2021 | |
| Insmed, INC. | $57.53 | 2025 | Arikayce |
| Ethicon INC. | $56.88 | 2024 | Monarch Platform |
| 3b Medical, INC. | $39.02 | 2024 | Luna |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $24.02 | 2019 | |
| Resmed Corp | $23.00 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Margolis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.